Vertex Pharmaceuticals Inc
Company Profile
Business description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact
50 Northern Avenue
BostonMA02210
USAT: +1 617 341-6100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6,100
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,828.70 | 2.30 | 0.03% |
CAC 40 | 7,765.02 | 41.55 | 0.54% |
DAX 40 | 24,205.07 | 131.40 | 0.55% |
Dow JONES (US) | 44,273.79 | 132.57 | -0.30% |
FTSE 100 | 8,847.72 | 41.19 | 0.47% |
HKSE | 24,148.07 | 260.24 | 1.09% |
NASDAQ | 20,387.30 | 25.22 | -0.12% |
Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
S&P 500 | 6,221.37 | 8.61 | -0.14% |
S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
SSE Composite Index | 3,497.48 | 24.35 | 0.70% |